Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Hiroshima J Med Sci
; 60(3): 57-62, 2011 Sep.
Article
en En
| MEDLINE
| ID: mdl-22053701
ABSTRACT
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Tirosina
/
Levodopa
/
Catecoles
/
Inhibidores Enzimáticos
/
Nitrilos
/
Antiparkinsonianos
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
En
Revista:
Hiroshima J Med Sci
Año:
2011
Tipo del documento:
Article
País de afiliación:
Japón